logo
  

USANA Health Sciences Lowers FY21 Outlook, Shares Down 3%

Shares of USANA Health Sciences Inc. (USNA) slipped 3% in extended session on Thursday after the company lowered its financial outlook for fiscal year 2021.

The company now expects full year 2021 earnings of $5.80 to $6.00 per share and revenues of $1.18 billion to $1.20 billion. Previously, the company expected earnings of $6.15 to $6.50 per share on revenues of $1.24 to $1.28 billion.

The company currently anticipates third quarter sales of $265 million to $270 million and earnings of $1.28 and $1.33 per share.

"Our sales results for the third quarter have been softer than we anticipated, largely because of increased disruptions and lockdowns in several of our markets due to the escalation of the COVID-19 pandemic," said Kevin Guest, Chief Executive Officer and Chairman of the Board.

USNA closed Thursday's trading at $87.46, down $0.05 or 0.06%, on the Nasdaq. The stock further slipped $2.69 or 3.08% in the after-hours trade.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
This Black Friday and the following holiday season, retailers across the United States are urged to keep up their inventory amid expected surge in shopping as majority of Americans wait till last minute to fill their baskets, according to certain studies. A new Oracle Retail survey, which was conducted last week and presented earlier this week, showed that 66 percent of consumers were less than Eagle, Idaho -based Flagship Food Group is recalling certain TJ Farms Select brand frozen cauliflower, citing the potential to be contaminated with Listeria monocytogenes, the U.S. Food and Drug Administration said. The recall involves a limited number of cases of TJ Farms Select cauliflower that comes in 16 oz. packages with lot code 2077890089 and UPC code 75544000604-3. The U.S. Food and Drug Administration has approved Takeda Pharmaceuticals Co. Ltd.'s Livtencity (maribavir) as the first drug to treat post-transplant cytomegalovirus or CMV in adults and pediatric patients. The approval is to treat patients 12 years of age and older and weighing at least 35 kilograms with post-transplant CMV infection/disease that does not respond...
Follow RTT